Published: 28 September 2023
Author(s): Chi Pang Wen, Min Kuang Tsai, June Han Lee, Hung Yi Chiou, Christopher Wen, Ta-Wei David Chu, Chien Hua Chen
Issue: March 2024
Section: Original article

The introduction of the fecal immunochemical test (FIT) for colorectal cancer (CRC) screening has brought significant advantages over the previous guaiac fecal occult blood test (gFOBT), particularly regarding the need for dietary restrictions [1–3]. More crucially, FIT has transformed the qualitative assessment of gFOBT, limited to positive or negative results, into a quantitative evaluation of CRC risk [4]. Approximately 5 % (ranging from 3 % to 6 %) of FIT would be found positive [4], with positive FIT commonly defined as ≧20 μg Hb/g of feces.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.